What Jideytro's Approval Means for Drug Developers

The FDA has approved Jideytro (zidesamtinib), a ROS1-selective kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have already received a prior ROS1 kinase inhibitor.1 GSK announced the approval, which arrived ahead of the agency's original target action date of September 18, 2026, following Breakthrough Therapy and Orphan Drug designations.

ROS1-positive NSCLC is a genetically defined subset of the disease, diagnosed in roughly 50,000 people worldwide each year.1 Patients tend to be non-smokers in their 40s and 50s, and many remain on treatment for years, making durability and tolerability especially consequential over time.

Why Does Resistance Keep Resurfacing in this Patient Population?

Even as ROS1 inhibitors have improved outcomes, resistance mutations, disease progression in the brain, and treatment-related side effects continue to limit how long patients benefit from any single therapy.1 Jideytro was designed to address these gaps: it combines high selectivity for ROS1, broad coverage of known resistance mutations, and the ability to cross the blood-brain barrier to reach disease that has spread to the central nervous system.

The approval rests on data from ARROS-1, a global phase I/II trial enrolling patients with advanced ROS1-positive NSCLC previously treated with a ROS1 inhibitor.1 Among 117 patients evaluated, the objective response rate was 44%, with response durability rates of 82% at six months and 69% at 12 months, including responses among patients with brain metastases and resistance mutations. In a pooled safety population of 446 patients, the most frequent adverse reactions occurring in at least 15% of patients were edema, peripheral neuropathy, constipation, fatigue, and difficulty breathing.

Alexander Drilon, a trial investigator and chief of the Early Development Service, Memorial Sloan Kettering Cancer Center, said in a press release.1 "Despite advances in treatment, resistance mutations, disease progression in the brain and treatment-related adverse events continue to create challenges for patients. The responses observed in ARROS-1, including in heavily pre-treated patients, represent meaningful progress for people living with this disease."

What Does this Approval Signal for Drug Developers Working in Targeted Oncology?

The path behind Jideytro illustrates a now-familiar model: acquiring a clinical-stage asset built around a validated target and advancing it quickly through regulatory review.1 Jideytro originated in GSK's recently completed acquisition of Nuvalent, and its approval marks GSK's first in lung cancer.2 The company is continuing to develop other candidates from that acquisition, including a treatment for ALK-altered lung cancer under FDA review and an early-stage treatment for HER2-altered disease.

The case also reflects how newer kinase inhibitors are increasingly engineered from the outset to solve the specific failure modes of earlier drugs in the same class, resistance mutations and limited penetration into the central nervous system chief among them, rather than treating those problems as issues to address later.1 That shift carries implications for how development programs design trials, select biomarkers, and plan for sequential or combination use of therapies within a target class.

Janet Freeman-Daily, co-founder and president, the ROS1ders, stated in a press release,1 "For patients, the goal is not just more time, but quality time to live life as normally as possible while on treatment. The ROS1-positive community is deeply invested in advancing care with treatments that are effective and tolerable. Today's approval gives patients and their doctors an important new option and represents meaningful progress for our community."

Where Did the Assets Behind Jideytro's Approval Originate?

Jideytro's approval traces directly to GSK's completed acquisition of Nuvalent.2 The deal, completed via tender offer, carried an aggregate equity value of approximately $10.6 billion, and brought three lung cancer assets into GSK's portfolio: zidesamtinib, neladalkib for ALK-altered NSCLC, and an early-stage HER2-altered candidate. Luke Miels, GSK's chief executive officer, said: "Today's deal completion accelerates our entry into lung cancer with zidesamtinib and neladalkib and a platform for rapid expansion with Ris-Rez, our B7-H3 targeted ADC in phase III development."

References

1. GSK. Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer. News release. July 22, 2026. https://www.gsk.com/en-gb/media/press-releases/jideytro-zidesamtinib-approved-in-the-us-for-previously-treated-ros1-positive-non-small-cell-lung-cancer/
2. GSK plc. GSK completes acquisition of Nuvalent, Inc. News release. July 14, 2026. https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-nuvalent-inc/